Login to Your Account

Start-up Amcure raises $7M to target CD44v6 in cancer

By Cormac Sheridan
Staff Writer

Thursday, July 24, 2014
German start-up Amcure GmbH raised €5 million (US$6.7 million) in a series A round to take forward a preclinical drug development program in cancer based on targeting a variant of the CD44 receptor, called CD44v6, which is implicated in both angiogenesis and metastasis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription